Get started
Award

Type 1 Diabetes TrialNet: Clinical Center at Berrie Center, Columbia University

Description: PUBLIC HEALTH RELEVANCE: Type 1 Diabetes TrialNet studies are designed to address the treatment, prevention and natural history of type 1 diabetes.
Funding type: cooperative_agreement
Funder scheme: U01
Start date: 2009-09-30
End date: 2014-05-31
Investigator: RAPHAEL A. CLYNES
Institution: COLUMBIA UNIVERSITY HEALTH SCIENCES
Subfield: Genetics
Funded outputs count: 101
Funder award ID: U01DK085504
OpenAlex ID: G4923436584
Phase I Clinical Trial of Islet Antigen–Specific Plasmid Coexpressing Tolerogenic Proteins Demonstrates Safety in Adults With Type 1 Diabetes
2026 · Carla J. Greenbaum, S. Alice Long, et al. · Diabetes · 3
Type 2 Diabetes Genetic Risk and Type 1 Diabetes Heterogeneity and Progression
2025 · Taylor M. Triolo, Jay M. Sosenko, et al. · Diabetes · 3
Genetic Predictors of Response to Oral Insulin for Type 1 Diabetes Prevention
2025 · Lu You, Hemang M. Parikh, et al. · Diabetes Care
PDF
Circulating senescence-associated secretory phenotype factors across the stages of type 1 diabetes in a cross-sectional cohort
2025 · Camille Préfontaine, Jasmine Pipella, et al. · Scientific Reports · 6
PDF
Baseline Insulin Secretion Determines Response to Abatacept in Stage 1 Type 1 Diabetes
2025 · Alfonso Galderisi, Alice L.J. Carr, et al. · Diabetes · 4
Stage 1 type 1 diabetes memory B lymphocytes transcriptionally differ from healthy controls and harbor insulin-binding specificities
2025 · Lindsay E Bass, Wyatt J McDonnell, et al. · ImmunoHorizons · 2
Neutrophil-enriched gene signature correlates with teplizumab therapy resistance in different stages of type 1 diabetes
2025 · Gabriele Sassi, Pierre Lemaitre, et al. · Journal of Clinical Investigation · 4
PDF
Novel Approach for Assessing Outcomes of Type 1 Diabetes Prevention Trials Over a Fixed Time Interval
2025 · Emily K. Sims, William E. Russell, et al. · Diabetes · 3
Prevention of diabetic ketoacidosis in relatives screened for islet autoantibodies and followed up in the TrialNet Pathway to Prevention study at a single institution in Italy
2025 · Sabina Martinenghi, Aurora Merolla, et al. · Diabetologia · 8
PDF
Evaluation of proinsulin(F25D) as a targeting ligand for insulin-binding B cells in autoimmune diabetes
2025 · Kyle D. Apley, Lindsay E. Bass, et al. · Drug Delivery and Translational Research · 4
Type 1 Diabetes TrialNet: Leading the Charge in Disease Prediction, Prevention, and Immunotherapeutic Mechanistic Understanding
2025 · Laura M. Jacobsen, Jamie L. Felton, et al. · Diabetes Care · 19
PDF
M120 Risk Score Improves Identification of Children at High Risk of Developing Clinical Type 1 Diabetes and Reports Short-term Response to Preventive Immunotherapy
2025 · Minh V. Le,, Leonard C. Harrison, et al. · Diabetes Care · 4
PDF
Activated polyreactive B cells are clonally expanded in autoantibody positive and patients with recent-onset type 1 diabetes
2025 · Catherine A. Nicholas, Fatima A. Tensun, et al. · Cell Reports · 12
Enhancing Type 1 Diabetes Immunological Risk Prediction with Continuous Glucose Monitoring and Genetic Profiling
2024 · Eslam Montaser, Leon S. Farhy, et al. · Diabetes Technology & Therapeutics · 36
Trajectory of beta cell function and insulin clearance in stage 2 type 1 diabetes: natural history and response to teplizumab
2024 · Alfonso Galderisi, Emily K. Sims, et al. · Diabetologia · 17
PDF
Teplizumab induces persistent changes in the antigen-specific repertoire in individuals at risk for type 1 diabetes
2024 · Ana Lledó-Delgado, Paula Preston-Hurlburt, et al. · Journal of Clinical Investigation · 59
PDF
Genetic Associations With C-peptide Levels Before Type 1 Diabetes Diagnosis in At-risk Relatives
2024 · Taylor M Triolo, Hemang M Parikh, et al. · The Journal of Clinical Endocrinology & Metabolism · 7
Early Metabolic Endpoints Identify Persistent Treatment Efficacy in Recent-Onset Type 1 Diabetes Immunotherapy Trials
2024 · Laura M. Jacobsen, David Cuthbertson, et al. · Diabetes Care · 7
Comparisons of Metabolic Measures to Predict T1D vs Detect a Preventive Treatment Effect in High-Risk Individuals
2024 · Emily K Sims, David Cuthbertson, et al. · The Journal of Clinical Endocrinology & Metabolism · 10
PDF
Effect of Oral Insulin on Early Combined Glucose and C‐Peptide Endpoints in Individuals at High‐Risk for Type 1 Diabetes
2024 · Taylor M. Triolo, Laura M. Jacobsen, et al. · Pediatric Diabetes · 1
PDF
Response to Comment on Russell et al. Abatacept for Delay of Type 1 Diabetes Progression in Stage 1 Relatives at Risk: A Randomized, Double-Masked, Controlled Trial. Diabetes Care 2023;46:1005–1013
2023 · William E. Russell, Daniel J. Moore, et al. · Diabetes Care · 5
PDF
Hydroxychloroquine in Stage 1 Type 1 Diabetes
2023 · Ingrid Libman, Polly J. Bingley, et al. · Diabetes Care · 18
PDF
High proinsulin:C-peptide ratio identifies individuals with stage 2 type 1 diabetes at high risk for progression to clinical diagnosis and responses to teplizumab treatment
2023 · Emily K. Sims, Susan M. Geyer, et al. · Diabetologia · 26
PDF
Phenotypes Associated With Zones Defined by Area Under the Curve Glucose and C-peptide in a Population With Islet Autoantibodies
2023 · Jay M. Sosenko, David Cuthbertson, et al. · Diabetes Care · 13
Abatacept for Delay of Type 1 Diabetes Progression in Stage 1 Relatives at Risk: A Randomized, Double-Masked, Controlled Trial
2023 · William E. Russell, Brian N. Bundy, et al. · Diabetes Care · 109
PDF
Year
Topic